Table 1. Patient and tumour characteristics.
ODX group, patients with cancers that were genetically profiled through Oncotype DX testing; non-ODX group, patients that did not have Oncotype DX testing.
Abbreviation: Oncotype DX (ODX)
| All patients | ODX group | Non-ODX group | |
| Patients, N | 133 | 46 | 87 |
| Age (years), mean | 62 | 56 | 65 |
| Disease identified through symptoms, n (%) | 68 (51.1%) | 32 (69.6%) | 36 (41.4%) |
| Disease detected through screening, n (%) | 65 (48.9%) | 14 (30.4) | 51 (58.6%) |
| Single-site disease, n (%) | 119 (89.5%) | 38 (82.6%) | 81 (93.1%) |
| Multifocal disease, n (%) | 14 (10.5%) | 8 (17.4%) | 6 (6.9%) |
| Tumours, n | 152 | 57 | 95 |
| Tumour size (cm), median | 2.0 | 2.4 | 1.6 |
| T1a (<5mm), n (%) | 3 (1.9%) | 1 (1.8%) | 2 (2.1%) |
| T1b (<10mm), n (%) | 16 (10.2%) | 3 (5.3%) | 13 (13.7%) |
| T1c (<20mm), n (%) | 52 (33.1%) | 13 (22.8%) | 39 (41.1%) |
| T2 (>20mm), n (%) | 72 (45.9%) | 32 (56.1%) | 40 (42.1%) |
| T3 (>50mm), n (%) | 9 (5.9%) | 8 (14.0%) | 1 (1.1%) |
| T4 (>50mm with chest wall or skin invasion), n (%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Tumour grade, median | 2 | 3 | 2 |
| Grade 1, n (%) | 28 (18.4%) | 2 (3.5%) | 26 (27.4%) |
| Grade 2, n (%) | 81 (53.3%) | 26 (45.6%) | 55 (57.9%) |
| Grade 3, n (%) | 43 (28.3%) | 29 (50.9%) | 14 (14.7%) |